Arcticzymes Technologies ASA
OSE:AZT

Watchlist Manager
Arcticzymes Technologies ASA Logo
Arcticzymes Technologies ASA
OSE:AZT
Watchlist
Price: 21.8 NOK -0.46% Market Closed
Market Cap: 1.1B NOK
Section:
 

Relative Value

The Relative Value of one AZT stock under the Base Case scenario is 23.46 NOK. Compared to the current market price of 21.8 NOK, Arcticzymes Technologies ASA is Undervalued by 7%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZT Relative Value
Base Case
23.46 NOK
Undervaluation 7%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

11.4
P/S
P/S
Price to Sales
11.4
vs History
74
vs Industry
47
Median 3Y
12.7
Median 5Y
17
Industry
7.8
Forward
9.9
More Details
397.1
P/E
P/E
Price to Earnings
397.1
vs History
7
vs Industry
1
Median 3Y
110.7
Median 5Y
87.2
Industry
24.1
Forward
159.9
More Details
105.5
P/OCF
P/OCF
Price to OCF
105.5
vs History
20
vs Industry
0
Median 3Y
71.2
Median 5Y
65.6
Industry
21.8
More Details
615
P/FCFE
P/FCFE
Price to FCFE
615
vs History
11
vs Industry
0
Median 3Y
128.3
Median 5Y
80.4
Industry
23.8
More Details
3.4
P/B
P/B
Price to Book Value
3.4
vs History
79
vs Industry
33
Median 3Y
4.4
Median 5Y
6.9
Industry
3.3
More Details
8.9
EV/S
EV/S
Enterprise Value to Sales
8.9
vs History
79
vs Industry
43
Median 3Y
10.7
Median 5Y
15
Industry
8
Forward
7.7
More Details
9.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.4
vs History
79
vs Industry
48
Median 3Y
11.2
Median 5Y
15.6
Industry
10.3
More Details
2 049.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
2 049.8
vs History
6
vs Industry
1
Median 3Y
82.6
Median 5Y
73.4
Industry
6.3
Forward
107.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
1
Median 3Y
57.7
Median 5Y
68.8
Industry
6.7
Forward
-862.6
More Details
82.6
EV/OCF
EV/OCF
Enterprise Value to OCF
82.6
vs History
25
vs Industry
0
Median 3Y
62.8
Median 5Y
61.8
Industry
7.9
More Details
158.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
158.5
vs History
20
vs Industry
1
Median 3Y
94.2
Median 5Y
73.3
Industry
6.3
More Details
9.6
EV/IC
EV/IC
Enterprise Value to IC
9.6
vs History
74
vs Industry
32
Median 3Y
12.1
Median 5Y
22.7
Industry
5.5
More Details

Multiples Across Competitors

AZT Competitors Multiples
Arcticzymes Technologies ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Arcticzymes Technologies ASA
OSE:AZT
1.1B NOK 11.4 397.1 2 049.8 -113.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 678 969.3 -160 071.1 -194 377.4 -192 159.4
US
Abbvie Inc
NYSE:ABBV
406.3B USD 6.8 173 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
179.7B USD 5 25.6 18.4 18.4
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD 5.4 19.2 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD 10 32 23.5 24.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 091.8 -533.8 -581.2 -565.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD 5.8 18 17.2 19.5
AU
CSL Ltd
ASX:CSL
83B AUD 3.6 18.5 12.5 15.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD 16.5 1 212.2 163.5 198.2
NL
argenx SE
XBRU:ARGX
44B EUR 14.4 33.8 58.2 59.8
P/E Multiple
Earnings Growth PEG
NO
Arcticzymes Technologies ASA
OSE:AZT
Average P/E: 214.4
397.1
64%
6.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 071.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
173
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
9%
2
AU
CSL Ltd
ASX:CSL
18.5
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 212.2
N/A N/A
NL
argenx SE
XBRU:ARGX
33.8
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBITDA: 263.7
2 049.8
111%
18.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 377.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.5
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBIT: 46.6
Negative Multiple: -113.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 159.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.4
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.5
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.5
13%
1.5
AU
CSL Ltd
ASX:CSL
15.6
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198.2
N/A N/A
NL
argenx SE
XBRU:ARGX
59.8
N/A N/A

See Also

Summary
AZT intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZT stock valuation using valuation multiples.
Wall Street Estimates
AZT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 305,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.